Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.49 |
| ▸ | KMO | O15229 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL901207 | 1.00 | TSHR (0.57) | TSHRTP53HDAC8HDAC6HDAC1 | |
| SCHEMBL901209 | 1.00 | TSHR (0.57) | TSHRTP53HDAC8HDAC6HDAC1 | |
| Hydrochloric Acid SCHEMBL4290507 | 0.98 | TSHR (0.55) | TSHRTP53HDAC8HDAC6HDAC1 | |
| SCHEMBL24087489 | 0.94 | HDAC8 (0.56) | TSHRTP53HDAC8HDAC6HDAC1 | |
| SCHEMBL28005910 | 0.92 | ESR2 (0.59) | TSHRTP53HDAC8HDAC6HDAC1 | |
| SCHEMBL9472162 | 0.91 | TSHR (0.52) | TSHRTP53HDAC8HDAC6HDAC1 | |
| SCHEMBL3495930 | 0.91 | HDAC8 (0.63) | TSHRTP53HDAC8HDAC6HDAC1 | |
| SCHEMBL13266972 | 0.91 | HDAC8 (0.58) | TSHRTP53HDAC8HDAC6HDAC1 | |
| SCHEMBL13186036 | 0.90 | ESR2 (0.60) | TSHRTP53HDAC8HDAC6HDAC1 | |
| SCHEMBL6686098 | 0.90 | NPC1 (0.66) | TSHRTP53HDAC8HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117658749-B | Method for preparing aryl carboxylic acid by reacting copper compound catalyzed aryl sulfonium salt with carbon dioxide | NANKAI UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2025-12-25 | — | — | US | disclosed |
| EP-4572762-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2025-06-25 | — | — | EP | disclosed |
| US-12281108-B2 | Pyrrolidinone derivatives as formyl peptide 2 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250122223-A1 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| WO-2025008058-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| EP-4466072-A1 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | Almac Discovery Limited (GB) | 2024-11-27 | — | — | EP | disclosed |
| CN-118946566-A | Heterocyclic compounds as ubiquitin-specific protease 7 inhibitors | 阿尔麦克探索有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-118652243-A | Peroxisome proliferator-activated receptor (PPARs) agonist, preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2024-09-17 | — | — | CN | disclosed |
| US-20090170921-A1 | Benzimidazole derivatives | NOVARTIS AG (CH) | 2009-07-02 | — | — | US | disclosed |
| WO-2009074487-A1 | INHIBITORS OF STEAROYL-COA DESATURASE | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | WO | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| WO-2009072643-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-11 | — | — | WO | disclosed |
| US-20090149466-A1 | INHIBITORS OF STEAROYL-COA DESATURASE | GILLESPIE PAUL | 2009-06-11 | — | — | US | disclosed |
| US-20080300243-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. | 2008-12-04 | — | — | US | disclosed |
| CN-1930133-A | Benzimidazole derivatives | NOVARTIS AG (CH) | 2007-03-14 | — | — | CN | disclosed |
| EP-1709006-A1 | BENZIMIDAZOLE DERIVATIVES | Novartis AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005068433-A9 | BENZIMIDAZOLE DERIVATIVES | NOVARTIS AG (CH) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005068433-A1 | BENZIMIDAZOLE DERIVATIVES | NOVARTIS AG (CH) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170921-A1 | Benzimidazole derivatives | CYP3A7, UGT2B7, CYP2B6 | TSHR 575/4885TP53 991/4885HDAC8 22/4885 |
| US-12281108-B2 | Pyrrolidinone derivatives as formyl peptide 2 receptor agonists | FPR1, FPR2, FPR3 | TSHR 747/4885TP53 4367/4885HDAC8 3772/4885 |
| US-20090149466-A1 | INHIBITORS OF STEAROYL-COA DESATURASE | SCD, SCD5, FADS2 | TSHR 3235/4885TP53 4864/4885HDAC8 584/4885 |
| US-20250122223-A1 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, SENP7 | TSHR 4655/4885TP53 298/4885HDAC8 274/4885 |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | TSHR 1206/4885TP53 4753/4885HDAC8 614/4885 |
| US-20080300243-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | TRPV1, TRPA1, TRPV2 | TSHR 2775/4885TP53 4006/4885HDAC8 796/4885 |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | TSHR 396/4885TP53 4801/4885HDAC8 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.